<DOC>
	<DOCNO>NCT02794480</DOCNO>
	<brief_summary>The study conduct evaluate potentially improve patient handle ELLIPTA Dry Powder Inhaler ( DPI ) . Therefore , study aim evaluate error encounter subject asthma handle ELLIPTA DPI relative two meter dose inhaler ( MDI ) , GSK MDI AstraZeneca ( AZ ) MDI . It randomise , multi-centre , open-label , cross-over study compare placebo ELLIPTA DPI placebo MDI ( GSK AZ ) ass correct inhaler use . No active drug use study order prevent drug-related effect . Approximately , 152 subject randomize receive ELLIPTA DPI inhaler 152 randomize receive one MDI inhaler , use first period ( P ) ( approximately 28 day ) . At Visit 2 ( Day 28 ) subject previous receive ELLIPTA DPI randomize receive one MDI inhaler subject receive MDI previous period receive ELLIPTA DPI use second period ( approximately 28 day ) . Subjects continue take asthma maintenance treatment limit rescue albuterol MDI entire 56-day study period . ELLIPTA register trademark GSK group company .</brief_summary>
	<brief_title>Phase IV Study Asthma Subjects Dry Powder Inhaler ( DPI ) Versus ( v ) Metered Dose Inhaler ( MDI ) Correct Use</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Subjects age 18 year old , time signing informed consent Documented history moderate persistent asthma Asthma Control Test ( ACT ) score &gt; =20 Male Females ( pregnant planning pregnancy study lactate ) Capable give sign informed consent include compliance requirement restriction Subject understands willing , able , likely comply study procedure restriction Subject must able read , comprehend , record information English Should receive maintenance therapy via MDI ELLIPTA past six month ( DISKUS ( trade name own GSK group company license ) , TWISTHALER ( trade name own Merck Sharp &amp; Dohme Corporation , subsidiary Merck &amp; Co , license , etc acceptable ) . Subject must maintenance therapy 3 month , change dose month prior inclusion able continue use maintenance therapy throughout study Requires Shortactingbetaagonist ( SABA ) symptom control = &lt; 2 days/week . Use SABA prior exercise prevention exercise induce bronchoconstriction exclusionary . Subjects know suspected alcohol drug abuse Visit 1 opinion investigator could interfere subject 's proper completion protocol requirement Current smoker subject smoke history 10 packyears ( example , 20 cigarettes/day 10 year ) eligible . A subject may use tobacco product within past year ( i.e. , cigarette , cigar , pipe tobacco ) Concurrent diagnosis chronic obstructive pulmonary disease ( COPD ) respiratory disorder include active tuberculosis , lung cancer , bronchiectasis , sarcoidosis , lung fibrosis , pulmonary hypertension , interstitial lung disease active pulmonary disease History life threaten asthma experience 1 exacerbation require oral/systemic corticosteroid 12 month prior Visit 1 History hypersensitivity component study inhaler ( e.g. , lactose , magnesium stearate ) . In addition , subject history severe milk protein allergy , opinion study physician , contraindicate participation Historical current evidence clinically significant rapidly progress unstable cardiovascular , neurological , cardiovascular , neurological , renal , hepatic , immunological , endocrine ( include uncontrolled diabetes thyroid disease ) hematological abnormality uncontrolled . Significant define disease , opinion investigator , would put safety subject risk participation , would affect affect analysis disease/condition exacerbate study Subjects receive investigational drug and/or medical device within 30 day entry study ( Screening/Visit 1 ) , within five drug halflives investigational drug , whichever longer A subject eligible study he/she immediate family member participate investigator , subinvestigator , study coordinator , employee participate investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ELLIPTA</keyword>
	<keyword>meter dose inhaler</keyword>
	<keyword>Dry powder inhaler</keyword>
</DOC>